Consun Pharmaceutical Group adopts revised governing documents

Consun Pharmaceutical Group Limited, whose registered office is in the Cayman Islands, has adopted its Third Amended and Restated Memorandum and Articles of Association following a Special Resolution passed on December 23, 2025. The company's authorised share capital remains HK$500,000,000, divided into 5,000,000,000 shares of HK$0.1 each. The updated articles specify that every director shall be subject to retirement by rotation at least once every three years, and the number of directors shall not be less than two.

The revised articles clarify procedures for general meetings, including quorum requirements and voting rights. Shareholders are entitled to one vote per share on a poll, and multiple proxies can be appointed by a shareholder that is a Clearing House. The company retains the power to purchase or redeem its own shares, provided it is authorised by an Ordinary Resolution of shareholders and aligns with relevant regulations issued by the HK Stock Exchange and/or the Securities and Futures Commission of Hong Kong.

Furthermore, the updated documents detail the company's borrowing powers, allowing the Board to raise or secure funds through debentures, debenture stock, bonds, or other securities. Provisions for untraceable shareholders have been outlined, allowing the company to sell shares if dividends remain unclaimed for 12 years and an advertisement of intent to sell has been published.